Apart from prescription drug struggles, for the first time, Walgreens executives also seemed to acknowledge fallout from the acquisition of health insurer Aetna by rival CVS Health Corp. Other pharmaceutical news focuses on congressional drug pricing efforts, the ghosts of J.P. Morgan's past, and a look ahead to 2020.
from Kaiser Health News https://ift.tt/2R1lA7N
January 09, 2020
Rose
Health News, Kaiser Health News
No comments
Related Posts:
Por qué ni siquiera la presión presidencial podría acelerar las vacunas contra covidMiles de estadounidenses están muriendo a causa de covid-19, pero los esfuerzos para aumentar la producción de vacunas que potencialmente salvan vidas están en un callejón sin salida. Moderna y Pfizer-BioNTech, los fabricante… Read More
Poll: Nearly Half of American Adults Now Want the Covid Vaccine — ASAPUse Our Content It can be republished for free. Americans’ reluctance to get vaccinated for covid-19 is waning, according to a poll released Wednesday. Nearly half of adults surveyed in January said they have either already b… Read More
If I Have Cancer, Dementia or MS, Should I Get the Covid Vaccine?As public demand grows for limited supplies of covid-19 vaccines, questions remain about the vaccines’ appropriateness for older adults with various illnesses. Among them are cancer patients receiving active treatment, dement… Read More
Remdesivir, Given to Half of Hospitalized Covid Patients in U.S., Is Big Win for Gilead — Boosted by TaxpayersIt was the end of April — just as the U.S. confirmed its millionth covid-19 case and 50,000 deaths — when White House adviser Dr. Anthony Fauci announced “highly significant” news about a drug called remdesivir. That was surp… Read More
Encuesta: casi la mitad de los adultos ahora quiere vacunarse contra covid lo antes posibleLa renuencia de los estadounidenses a vacunarse contra covid-19 está disminuyendo, según una encuesta publicada el miércoles 27 de enero. Casi la mitad de los adultos encuestados en enero dijeron que ya han sido vacunados o q… Read More
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment